Asset profile
Patritumab Deruxtecan
Antibody–drug conjugate
Evidence outlook · lead readout
TUXEDO-3 (NCT05865990) · Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
The reported results come from study designs that frequently fail to replicate under controlled conditions; see the rationale below.
TUXEDO-3 (NCT05865990): The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
120 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 82 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Patritumab Deruxtecan: this drug | Phase 3 | Antibody–drug conjugate | HER3 | ||
| SHR-A2009 | Phase 3 | Antibody–drug conjugate | HER3 | ||
| AK138D1 | Phase 1/2 | Antibody–drug conjugate | HER3 | ||
| DB-1310 | Phase 1/2 | Antibody–drug conjugate | HER3 | ||
| ENV-501 | Phase 1/2 | Antibody–drug conjugate | HER3 | ||
| HMBD-001 | Phase 1/2 | Monoclonal antibody | HER3 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR |
…and 105 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (5)
April 2027 (2)
May 2027 (1)
What to watch
September 2027 (2)
What to watch
What to watch
2028 (2)
May 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
August 2029 (1)
What to watch
September 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (2)
2031 (1)
January 2031 (1)
What to watch
2032 (2)
2033 (1)
July 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.